| Online-Ressource |
Verfasst von: | Wohlfeil, Sebastian A. [VerfasserIn]  |
| Kranzmann, Leonie [VerfasserIn]  |
| Weiß, Christel [VerfasserIn]  |
| von Wasielewski, Imke [VerfasserIn]  |
| Klespe, Kai C. [VerfasserIn]  |
| Kähler, Katharina C. [VerfasserIn]  |
| Weichenthal, Michael [VerfasserIn]  |
| Schadendorf, Dirk [VerfasserIn]  |
| Zimmer, Lisa [VerfasserIn]  |
| Mohr, Peter [VerfasserIn]  |
| Meier, Friedegund [VerfasserIn]  |
| Pfoehler, Claudia [VerfasserIn]  |
| Berking, Carola [VerfasserIn]  |
| Heppt, Markus V. [VerfasserIn]  |
| Herbst, Rudolf [VerfasserIn]  |
| Kreuter, Alexander [VerfasserIn]  |
| Gutzmer, Ralf [VerfasserIn]  |
| Ulrich, Jens [VerfasserIn]  |
| Meiss, Frank [VerfasserIn]  |
| Gebhardt, Christoffer [VerfasserIn]  |
| Dippel, Edgar [VerfasserIn]  |
| Leiter, Ulrike [VerfasserIn]  |
| Schilling, Bastian [VerfasserIn]  |
| Ugurel, Selma [VerfasserIn]  |
| Utikal, Jochen [VerfasserIn]  |
Titel: | Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma |
Titelzusatz: | a multicenter study on 1383 patients of the prospective DeCOG registry ADOReg : cancer therapy and prevention |
Verf.angabe: | Sebastian A. Wohlfeil, Leonie Kranzmann, Christel Weiß, Imke von Wasielewski, Kai C. Klespe, Katharina C. Kähler, Michael Weichenthal, Dirk Schadendorf, Lisa Zimmer, Peter Mohr, Friedegund Meier, Claudia Pfoehler, Carola Berking, Markus V. Heppt, Rudolf Herbst, Alexander Kreuter, Ralf Gutzmer, Jens Ulrich, Frank Meiss, Christoffer Gebhardt, Edgar Dippel, Ulrike Leiter, Bastian Schilling, Selma Ugurel, Jochen Utikal |
E-Jahr: | 2024 |
Jahr: | 15 November 2024 |
Umfang: | 16 S. |
Fussnoten: | Erstmals veröffentlicht: 08. Juli 2024 ; Gesehen am 19.11.2024 |
Titel Quelle: | Enthalten in: International journal of cancer |
Ort Quelle: | Bognor Regis : Wiley-Liss, 1966 |
Jahr Quelle: | 2024 |
Band/Heft Quelle: | 155(2024), 10 vom: Nov., Seite 1808-1823 |
ISSN Quelle: | 1097-0215 |
Abstract: | This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received adjuvant therapies with Nivolumab (N), Pembrolizumab (P), or Dabrafenib and Trametinib (D + T) were extracted from the prospective multicenter real-world skin cancer registry ADOReg. Endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), organ-specific DMFS, and overall survival (OS). For primary cases, D + T indicated an improved PFS (1- and 2-year PFS: 90.9%; 82.7%) as compared to P (81.0%, 73.9%; p = .0208), or N (83.8%, 75.2%; p = .0539). BRAF-mutated(mut) CM demonstrated significantly lower PFS (p = .0022) and decreased DMFS (p = .0580) when treated with immune checkpoint inhibitor (ICI) instead of D + T. Besides, NRAS-mut CM tended to perform worse than wt CM upon ICI (PFS: p = .1349; DMFS: p = .0540). OS was similar between the groups. Relapsed cases showed decreased PFS, DMFS, and OS in comparison to primary (all: p < .001), without significant differences between the subgroups. Organ-specific DMFS was significantly altered for primary cases with bone (p = .0367) or brain metastases (p = .0202). In relapsed CM, the frequency of liver (D + T: 1.5%; P: 12%; N: 9%) and LN metastases (D + T: 1.5%; P: 12%; N: 10.2%) was significantly lower with adjuvant D + T than ICI. NRAS-mut CM showed increased recurrence in primary and relapsed cases. These data show that adjuvant D + T is superior to ICI in primary BRAF-mut CM. |
DOI: | doi:10.1002/ijc.35078 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1002/ijc.35078 |
| kostenfrei: Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.35078 |
| DOI: https://doi.org/10.1002/ijc.35078 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | adjuvant treatment |
| immune checkpoint inhibition |
| melanoma |
| targeted therapy |
| therapy resistance |
K10plus-PPN: | 1908954884 |
Verknüpfungen: | → Zeitschrift |
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma / Wohlfeil, Sebastian A. [VerfasserIn]; 15 November 2024 (Online-Ressource)